Key clinical point: In the real-world setting, secukinumab has a satisfactory retention rate in psoriatic arthritis (PsA). However, retention rates are lower in PsA than in psoriasis, with arthritis and obesity being significant predictors of shorter drug survival.
Major finding: Retention rate of secukinumab was higher in psoriasis vs. PsA at 12 ( 85% vs. 68% ) and 24 ( 61% vs. 57% ) months, with the risk for secukinumab discontinuation being higher among patients with arthritis in the overall cohort (hazard ratio 2.43; P = .035) and in patients with obesity in the PsA cohort ( P = .021).
Study details: Findings are from a real-life study including 62 patients with psoriasis and 90 patients with PsA who initiated treatment with secukinumab and were followed up for 24 months or until discontinuation.
Disclosures: This study did not receive any funding. R Ramonda and S Piaserico declared receiving honoraria and speaker fees form Novartis, Abbvie, Pfizer, MSD, and Janssen.
Source: Ortolan A et al. Secukinumab drug survival in psoriasis and psoriatic arthritis patients: A 24-month real-life study. Dermatology. 2022 (Mar 9). Doi: 10.1159/000522008